CN109789182A - 治疗干眼综合征的方法 - Google Patents

治疗干眼综合征的方法 Download PDF

Info

Publication number
CN109789182A
CN109789182A CN201780056154.4A CN201780056154A CN109789182A CN 109789182 A CN109789182 A CN 109789182A CN 201780056154 A CN201780056154 A CN 201780056154A CN 109789182 A CN109789182 A CN 109789182A
Authority
CN
China
Prior art keywords
subject
composition
des
illness
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056154.4A
Other languages
English (en)
Chinese (zh)
Inventor
梁元硕
姜信旭
金京洵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegenTree LLC
Original Assignee
RegenTree LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegenTree LLC filed Critical RegenTree LLC
Publication of CN109789182A publication Critical patent/CN109789182A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201780056154.4A 2016-07-18 2017-07-17 治疗干眼综合征的方法 Pending CN109789182A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363592P 2016-07-18 2016-07-18
US201662363565P 2016-07-18 2016-07-18
US62/363,565 2016-07-18
US62/363,592 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (1)

Publication Number Publication Date
CN109789182A true CN109789182A (zh) 2019-05-21

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056154.4A Pending CN109789182A (zh) 2016-07-18 2017-07-17 治疗干眼综合征的方法

Country Status (8)

Country Link
US (2) US10960051B2 (enExample)
EP (1) EP3484497A4 (enExample)
JP (1) JP6889771B2 (enExample)
KR (1) KR102488796B1 (enExample)
CN (1) CN109789182A (enExample)
AU (1) AU2017300268B2 (enExample)
CA (1) CA3031069A1 (enExample)
WO (1) WO2018017479A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1638789A (zh) * 2001-03-15 2005-07-13 雷金纳克斯生物制药公司 用胸腺素β4(Tβ4)、类似物、异构体及其它衍生物治疗眼睛和周围组织失调的方法
CN101102784A (zh) * 2005-01-13 2008-01-09 雷金纳克斯生物制药公司 对由神经退行性疾病、肌肉退行性疾病、或神经-肌肉退行性疾病所致的组织退化、伤害或损伤进行治疗或预防的方法、或对受到所述疾病的不利影响的组织进行恢复的方法
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
CN101549148A (zh) * 2001-08-29 2009-10-07 雷根内克斯生物制药有限公司 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用
CN105106931A (zh) * 2005-06-17 2015-12-02 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503527A (ja) 1990-02-22 1993-06-10 マクノート・ピーティーワイ・リミテッド 人工涙液
KR101258316B1 (ko) 2007-07-11 2013-04-30 화이자 인코포레이티드 안구 건조증 치료용 약학 조성물 및 방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN1638789A (zh) * 2001-03-15 2005-07-13 雷金纳克斯生物制药公司 用胸腺素β4(Tβ4)、类似物、异构体及其它衍生物治疗眼睛和周围组织失调的方法
CN101549148A (zh) * 2001-08-29 2009-10-07 雷根内克斯生物制药有限公司 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用
CN101102784A (zh) * 2005-01-13 2008-01-09 雷金纳克斯生物制药公司 对由神经退行性疾病、肌肉退行性疾病、或神经-肌肉退行性疾病所致的组织退化、伤害或损伤进行治疗或预防的方法、或对受到所述疾病的不利影响的组织进行恢复的方法
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
CN105106931A (zh) * 2005-06-17 2015-12-02 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《老干部之家》编辑部: "《我不是医生 我是健康老人 260名保健明星养生祛病经验集萃》", 31 January 2009 *
司信喜等: ""胸腺肽β_4研究进展"", 《生物技术通讯》 *
李平余: "《中老年人常见眼病》", 31 October 2014, 金盾出版社 *
陈峥: "《老年病诊疗手册》", 31 May 2012, 中国协和医科大学出版社 *

Also Published As

Publication number Publication date
JP2019525923A (ja) 2019-09-12
WO2018017479A1 (en) 2018-01-25
AU2017300268B2 (en) 2024-06-13
AU2017300268A1 (en) 2019-01-31
CA3031069A1 (en) 2018-01-25
KR20190031280A (ko) 2019-03-25
US20210213103A1 (en) 2021-07-15
US10960051B2 (en) 2021-03-30
EP3484497A1 (en) 2019-05-22
JP6889771B2 (ja) 2021-06-18
EP3484497A4 (en) 2020-01-01
KR102488796B1 (ko) 2023-01-13
US20190240294A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
Yeu et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)
AU2019358249B2 (en) Ophthalmic composition for treatment of dry eye disease
Kheirkhah et al. Corneal manifestations of ocular demodex infestation
Gaddie et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2)
Mastropasqua et al. Conjunctival goblet cells density and preservative‐free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study
JP7012075B2 (ja) 眼瞼炎の治療に使用するための医薬組成物
Mastropasqua et al. In vivo distribution of corneal epithelial dendritic cells in patients with glaucoma
US20090041855A1 (en) Therapeutic agent for ophthalmic diseases
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
Yamamoto et al. Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study
Aung et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
Ruangvaravate et al. Ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients
BR112020003276A2 (pt) métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
Cheema et al. Sodium hyaluronate eye drops in the treatment of dry eye disease: an open label, uncontrolled, multi-centre trial
Yeu et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle
Fan et al. Anthocyanin oligomer (grape skin extract) administration improves dry eye disease: A randomised, double‐blind, placebo‐controlled study
US20210213103A1 (en) Methods of treating dry eye syndrome
CN113453686A (zh) 治疗眼表痛的方法
Kaldırım et al. Efficacy of hyperbaric oxygen therapy on central corneal thickness, intraocular pressure, and nerve fiber layer in patients with type 2 diabetes: A prospective cohort study
Sakata et al. Time course of prostaglandin analog-related conjunctival hyperemia and the effect of a nonsteroidal anti-inflammatory ophthalmic solution
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
Kumar et al. Efficacy and Adverse Effects of Topical Latanoprost with Respect to Preservative in Patients of POAG.
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
RU2850452C2 (ru) Способы лечения боли на поверхности глаза

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012612

Country of ref document: HK